drugset / Trial / NCT02753426
A Trial of Doxycycline in Renal Disease
RandomizedCrossoverDouble-blindPrevention
Summary
The goal of this trial is to evaluate whether subantimicrobial-dose of doxycycline (20mgBID) will affect serum and urine biomarkers of fibrosis in patients with pre-dialysis chronic kidney disease.
Timeline
- Start
- 2016-04
- Primary completion
- 2017-12
- Completion
- 2018-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 20 mg | Oral |